...Characterization of Anaplastic Lymphoma Kinase fusion partner on DNA extracted from tissue biopsy and on cell-free nucleic acid (cfNA) (both cfDNA and cfRNA) extracted from plasma sample....

Pts with ALK fusions (ALK+) received alectinib 600 mg twice daily….In the overall population, ORR was 89.7% (95% CI 81.3–95.2); median DOR was 35.1 months (95% CI 24.8–49.7); 48-month OS rate was 58.3% (95% CI 47.8–68.7).

We enrolled 11patients from January 2019 to December 2022 at the Department of Thoracic Surgery II, Peking University Cancer Hospital & Institute with stage IIB-IIIB ALK-positive NSCLC who received Crizotinib or Alectinib as inductive treatment strategy before surgery....All patients were confirmed clinical stage IIB-IIIB and with ALK fusion mutation. Nine patients received ALK-TKI as initial inductive treatment, among which three (patient 1, 6 and 10) received crizotinib at dose of 250 mg twice daily and six (patient 2, 4, 7, 8, 9 and 11) received alectinib at dose of 600 mg twice daily....According to the radiologic assessment before surgery, nine patients (72.7%) achieved a partial regression (PR), and two patients (patient 2 and 6) remained SD.

Of the 65 patients with ALK-positve NSCLC who underwent treatment failure of crizotinib, 43 (66.2%) received alectinib and 22 (33.8%) received ceritinib...The median follow-up duration was 16.8 months and 32.0 months in the alectinib and ceritinib groups, respectively....The tumor response was estimable in 63 patients (41 treated with alectinib and 22 treated with ceritinib), with the CR and PR being 2.4 and 70.8%,respectively, in the alectinib group and the PR being 50% in the ceritinib group.

We herein report the case of a 42-year-old...was eventually diagnosed with non-small cell lung cancer (NSCLC) with MEC differentiation...Genetic testing for EGFR mutations was negative, but positive for anaplastic lymphoma kinase (ALK) fusion gene. After 2 weeks of first-line treatment with alectinib, the tumor decreased in size and his symptoms improved.